Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-10-23-Speech-2-524-750"
Predicate | Value (sorted: default) |
---|---|
rdf:type | |
dcterms:Date | |
dcterms:Is Part Of | |
dcterms:Language | |
lpv:document identification number |
"en.20121023.45.2-524-750"2
|
lpv:hasSubsequent | |
lpv:speaker | |
lpv:spokenAs | |
lpv:translated text |
"Sweden meets the conditions for deploying the European Globalisation Adjustment Fund and is therefore clearly entitled to financial assistance. The collective redundancies at AstraZeneca had not been expected, owing to Sweden’s strong position in the field of medical research. The pharmaceutical sector must contend with a rising number of generic medicines as patents gradually expire. At the same time, Sweden is opposed to the continued existence of the EGF after 2013. For that reason, I abstained from the vote."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples